Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SMO | Q99835 | 3/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | IDE | P14735 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4246155 | 0.89 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAKMT2ASMOPPARG | |
| SCHEMBL4069395 | 0.85 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAKMT2ASMOPPARG | |
| SCHEMBL4246923 | 0.84 | SMO (0.61) | SMN1; SMN2LMNAKMT2ASMOPPARG | |
| SCHEMBL4252387 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAKMT2ASMOPPARG | |
| SCHEMBL4248525 | 0.83 | PARP1 (0.48) | SMN1; SMN2LMNAKMT2ASMOPPARG | |
| SCHEMBL4245119 | 0.82 | SMN1; SMN2 (0.50) | SMN1; SMN2LMNAKMT2ASMOPPARG | |
| SCHEMBL4247565 | 0.81 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNAKMT2ASMOPPARG | |
| SCHEMBL4398189 | 0.81 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNAKMT2ASMOPPARG | |
| SCHEMBL4398116 | 0.81 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAKMT2ASMOPPARG | |
| SCHEMBL4070453 | 0.79 | SMN1; SMN2 (0.60) | SMN1; SMN2LMNAKMT2APPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2009-12-10 | — | — | US | claimed |
| EP-2057124-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM, LLC (BM) | 2009-05-13 | — | — | EP | claimed |
| WO-2008011611-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-01-24 | — | — | WO | claimed |
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2009-12-10 | — | — | US | disclosed |
| EP-2057124-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM, LLC (BM) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008011611-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IP6K1, IP6K2, IP6K3 | SMN1; SMN2 3497/4885LMNA 2895/4885KMT2A 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.